Morphic to participate in jefferies ibd therapeutics summit

Waltham, mass., oct. 12, 2021 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the morphic leadership team are scheduled to take part in a fireside chat at the jefferies virtual next generation ibd therapeutics summit on october 19, 2021 at 3:15 p.m. et.
MORF Ratings Summary
MORF Quant Ranking